Guoli Li1, Xinwu Guo2, Lili Tang3, Ming Chen2, Xipeng Luo2, Limin Peng2, Xunxun Xu2, Shouman Wang3, Zhi Xiao3, Wenjun Yi4, Lizhong Dai2,5,6, Jun Wang7. 1. The State Key Laboratory of Medical Genetics & School of Life Sciences, Central South University, 172 Tongzipo Road, Changsha, Hunan, 410013, China. 2. Sanway Gene Technology Inc., Changsha, Hunan, 410205, China. 3. Department of Breast Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China. 4. Department of Breast and Thyroid Surgery, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China. 5. Research Center for Technologies in Nucleic Acid-Based Diagnostics, Changsha, Hunan, 410205, China. 6. Research Center for Technologies in Nucleic Acid-Based Diagnostics and Therapeutics, Changsha, Hunan, 410205, China. 7. The State Key Laboratory of Medical Genetics & School of Life Sciences, Central South University, 172 Tongzipo Road, Changsha, Hunan, 410013, China. junwang@csu.edu.cn.
Abstract
PURPOSE: BRCA1 and BRCA2 (BRCA1/2) are two major high-penetrance breast cancer predisposition genes, mutations in which can lead to high risks and early onset of breast cancer. This study was performed to comprehensively investigate the spectrum and prevalence of BRCA1/2 mutations in unselected Chinese breast cancer patients and evaluate the associations of BRCA1/2 mutations with related clinicopathological characteristics of the tumors. METHODS: By integrating microfluidic PCR-based target enrichment and next-generation sequencing, paired tumor and normal tissues from 313 unselected breast cancer patients were analyzed for both germline and somatic mutations of BRCA1/2 genes in Chinese Han population. RESULTS: Total 5 BRCA1 and 8 BRCA2 deleterious germline mutations were detected in 5 (1.60%) and 12 (3.83%) of the 313 patients, respectively. The entire frequency of deleterious germline mutations of BRCA1/2 was 5.43%. Among them, c.1069A > T and c.3418_3419insTGACTACT in BRCA1, c.8474_8487delCATACCCTATACAG and c.6547delG in BRCA2 were novel. In addition, 32 germline variants of unknown significance in 31 (9.90%) of the 313 patients were identified. We also detected 13 somatic mutations in ten patients (3.19%), including 4 (1.28%) deleterious mutations (c.1575delT, c.2677C > T, c.7024C > T, and c.7672G > T in BRCA2) and 5 novel mutations (c.4728A > G and c.4820T > C in BRCA1; c.2527G > A, c.4069C > G and c.7672G > T in BRCA2). Notably, BRCA1 mutation carriers were significantly younger, and more likely to be ER negative and basal-like breast cancers. CONCLUSIONS: Our study provided a reliable and effective platform for BRCA1/2 genetic testing, and suggested that there was a relatively high prevalence and special spectrum of BRCA1/2 mutations in unselected Chinese breast cancer patients.
PURPOSE:BRCA1 and BRCA2 (BRCA1/2) are two major high-penetrance breast cancer predisposition genes, mutations in which can lead to high risks and early onset of breast cancer. This study was performed to comprehensively investigate the spectrum and prevalence of BRCA1/2 mutations in unselected Chinese breast cancerpatients and evaluate the associations of BRCA1/2 mutations with related clinicopathological characteristics of the tumors. METHODS: By integrating microfluidic PCR-based target enrichment and next-generation sequencing, paired tumor and normal tissues from 313 unselected breast cancerpatients were analyzed for both germline and somatic mutations of BRCA1/2 genes in Chinese Han population. RESULTS: Total 5 BRCA1 and 8 BRCA2 deleterious germline mutations were detected in 5 (1.60%) and 12 (3.83%) of the 313 patients, respectively. The entire frequency of deleterious germline mutations of BRCA1/2 was 5.43%. Among them, c.1069A > T and c.3418_3419insTGACTACT in BRCA1, c.8474_8487delCATACCCTATACAG and c.6547delG in BRCA2 were novel. In addition, 32 germline variants of unknown significance in 31 (9.90%) of the 313 patients were identified. We also detected 13 somatic mutations in ten patients (3.19%), including 4 (1.28%) deleterious mutations (c.1575delT, c.2677C > T, c.7024C > T, and c.7672G > T in BRCA2) and 5 novel mutations (c.4728A > G and c.4820T > C in BRCA1; c.2527G > A, c.4069C > G and c.7672G > T in BRCA2). Notably, BRCA1 mutation carriers were significantly younger, and more likely to be ER negative and basal-like breast cancers. CONCLUSIONS: Our study provided a reliable and effective platform for BRCA1/2 genetic testing, and suggested that there was a relatively high prevalence and special spectrum of BRCA1/2 mutations in unselected Chinese breast cancerpatients.
Entities:
Keywords:
BRCA1; BRCA2; Breast cancer; Microfluidic PCR; Mutation; Next-generation sequencing
Authors: Mary B Daly; Robert Pilarski; Jennifer E Axilbund; Michael Berry; Saundra S Buys; Beth Crawford; Meagan Farmer; Susan Friedman; Judy E Garber; Seema Khan; Catherine Klein; Wendy Kohlmann; Allison Kurian; Jennifer K Litton; Lisa Madlensky; P Kelly Marcom; Sofia D Merajver; Kenneth Offit; Tuya Pal; Huma Rana; Gwen Reiser; Mark E Robson; Kristen Mahoney Shannon; Elizabeth Swisher; Nicoleta C Voian; Jeffrey N Weitzel; Alison Whelan; Myra J Wick; Georgia L Wiesner; Mary Dwyer; Rashmi Kumar; Susan Darlow Journal: J Natl Compr Canc Netw Date: 2016-02 Impact factor: 11.908
Authors: Lu Yao; Jie Sun; Juan Zhang; Yingjian He; Tao Ouyang; Jinfeng Li; Tianfeng Wang; Zhaoqing Fan; Tie Fan; Benyao Lin; Yuntao Xie Journal: Breast Cancer Res Treat Date: 2016-03-31 Impact factor: 4.872
Authors: Ava Kwong; Enders Kai On Ng; Chris Lei Po Wong; Fian Bic Fai Law; Tommy Au; Hong Nei Wong; Allison W Kurian; Dee W West; James M Ford; Edmond Siu Kwan Ma Journal: PLoS One Date: 2012-09-07 Impact factor: 3.240
Authors: Yixiao Feng; Mia Spezia; Shifeng Huang; Chengfu Yuan; Zongyue Zeng; Linghuan Zhang; Xiaojuan Ji; Wei Liu; Bo Huang; Wenping Luo; Bo Liu; Yan Lei; Scott Du; Akhila Vuppalapati; Hue H Luu; Rex C Haydon; Tong-Chuan He; Guosheng Ren Journal: Genes Dis Date: 2018-05-12
Authors: Joyce O'Shaughnessy; Christine Brezden-Masley; Marina Cazzaniga; Tapashi Dalvi; Graham Walker; James Bennett; Shozo Ohsumi Journal: Breast Cancer Res Date: 2020-10-27 Impact factor: 6.466
Authors: Vanessa Lattimore; Michael T Parsons; Amanda B Spurdle; John Pearson; Klaus Lehnert; Jan Sullivan; Caroline Lintott; Suzannah Bawden; Helen Morrin; Bridget Robinson; Logan Walker Journal: Breast Cancer Res Treat Date: 2020-10-28 Impact factor: 4.872